KR20130052878A - Silk peptide effective for diabetes - Google Patents
Silk peptide effective for diabetes Download PDFInfo
- Publication number
- KR20130052878A KR20130052878A KR1020110118198A KR20110118198A KR20130052878A KR 20130052878 A KR20130052878 A KR 20130052878A KR 1020110118198 A KR1020110118198 A KR 1020110118198A KR 20110118198 A KR20110118198 A KR 20110118198A KR 20130052878 A KR20130052878 A KR 20130052878A
- Authority
- KR
- South Korea
- Prior art keywords
- silk
- molecular weight
- peptide
- calcium salt
- functional food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 49
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 230000006872 improvement Effects 0.000 claims abstract description 19
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 8
- 239000001110 calcium chloride Substances 0.000 claims abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 7
- 238000005903 acid hydrolysis reaction Methods 0.000 claims abstract 2
- 108010022355 Fibroins Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 11
- 238000000354 decomposition reaction Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 159000000007 calcium salts Chemical class 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 229940034586 silk sericin Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 229920000642 polymer Polymers 0.000 abstract description 15
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000225 effect on diabetes Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108010013296 Sericins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000255789 Bombyx mori Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 108091005995 glycated hemoglobin Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000382353 Pupa Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229910017053 inorganic salt Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/28—Hydrolysis, degree of hydrolysis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 당뇨에 개선 효과가 있는 고분자 실크 펩타이드의 구성물에 관한 것으로, 실크(견사)를 산 가수분해 방법 또는 염화칼슘을 이용하여 가수분해하여 동결 건조한 후, 분말상으로 제조한 고분자 실크 펩타이드 조성물로써, 본 발명의 실크 펩타이드의 분자량은 10,000~50,000 으로 체내에서 흡수되지 않아 혈당을 낮추는 기능성 식품 또는 의약품으로 개발하거나 각 성분에 대한 활성물질의 개발에 기여할 수 있다. The present invention relates to a composition of a polymer silk peptide having an improvement effect on diabetes, and is a polymer silk peptide composition prepared in a powder form after hydrolyzing silk (silk silk) using an acid hydrolysis method or calcium chloride, The molecular weight of the silk peptide of the present invention is 10,000 ~ 50,000 can not be absorbed in the body can be developed as a functional food or drug that lowers blood sugar or contribute to the development of active substances for each component.
Description
본 발명은 당뇨 개선 기능을 가지는 실크 펩타이드 조성물에 관한 것으로서, 보다 상세하게는 실크 단백질을 가수 분해하여 10,000~50,000의 중량 평균 분자량을 갖으며, 당뇨 개선의 기능을 발휘하는 고분자 실크 펩타이드 조성물에 관한 것이다.
The present invention relates to a silk peptide composition having a diabetic improvement function, and more particularly, to a polymer silk peptide composition having a weight average molecular weight of 10,000 to 50,000 by hydrolyzing silk protein and exhibiting a function of diabetic improvement. .
실크는 피브로인과 세리신으로 구성되어 있는 단백질계 섬유로 예전에는 옷감을 만드는 데에만 사용되었으나, 최근에는 연구에 의하여 기능성 식품 및 화장품으로 제조되어 사용되고 있다. 이러한 실크 단백질을 기능성 식품 또는 약제의 유효 성분으로 이용하기 위하여, 실크 단백질로부터 저분자 실크 펩타이드를 얻기 위한 다양한 방법이 제시되어 있다. 예컨대, 대한민국 특허등록 제 10-0443785 호에는 염산을 이용하여 실크 아미노산의 제조방법이 개시되어 있고, 대한민국 특허등록 제 10-0420824 호에는 알카리를 이용하여 실크 펩타이드를 제조하는 방법이 개시되어 있으며, 대한민국 특허등록 제 10-0881210 호에는 효소를 이용하여 실크 펩타이드를 제조방법이 개시되어 있다.Silk is a protein-based fiber composed of fibroin and sericin, which was previously used only for making fabrics, but recently has been manufactured and used as a functional food and cosmetics by research. In order to use such silk proteins as active ingredients of functional foods or pharmaceuticals, various methods for obtaining low molecular weight silk peptides from silk proteins have been proposed. For example, Korean Patent Registration No. 10-0443785 discloses a method for producing silk amino acids using hydrochloric acid, and Korean Patent Registration No. 10-0420824 discloses a method for preparing silk peptides using alkali, and Korea Patent Registration No. 10-0881210 discloses a method for producing silk peptides using enzymes.
또한 이렇게 제조된 분자량 100~2,000 정도의 저분자 실크 펩타이드에 대하여 당뇨 개선, 인지기능 개선 등의 효능이 있는 것이 여러가지 제시되어 있다. 예컨대, 대한민국 특허등록 제 10-0947547 호에는 당뇨의 치료 및 예방효과를 가지는 실크 펩타이드에 대한 내용이 개시되어 있고, 대한민국 특허등록 제 10-0494358 호에는 두뇌 인지 기능 개선에 효과가 있는 실크 펩타이드에 대한 내용이 개시되어 있다. In addition, the low molecular weight silk peptides having a molecular weight of about 100 to 2,000 thus produced have been shown to have various effects such as diabetes improvement and cognitive function. For example, Korean Patent Registration No. 10-0947547 discloses a silk peptide having a therapeutic and prophylactic effect of diabetes, and Korean Patent Registration No. 10-0494358 discloses a silk peptide effective for improving brain cognitive function. The contents are disclosed.
종래의 실크 펩타이드 제조방법들은 염산 또는 효소를 이용하여 섬유형태의 실크 견사를 가수분해하여 분자량이 작은 저분자 펩타이드나 아미노산 수준으로 아주 작게 분해하는 방법을 개발하는데 초점을 맞추어져 있었다. 따라서 최종 제품의 분자량은 대부분 100 ~ 2,000 정도의 아미노산이나 저분자 펩타이드 정도 크기의 수준이며, 가수분해된 생성물 중에 커다란 것의 분자량도 10,000 내외의 것들로 이루어져 있다. 견사 섬유는 그 자체로는 소화 흡수될 수 없기 때문에 그동안 여러가지 방법을 이용하여 저분자화하여 어떻게 하면 소화 흡수율을 높일 수 있을까에 초점을 맞춘 연구가 이루어져 왔으며, 개발된 가장 대표적인 방법이 산과 효소를 이용하여 가수분해하는 방법이다. 산과 효소에 의해 저분자화된 아미노산이나 저분자 펩타이드는 90% 이상 인체에 흡수될 수 있었으며, 이렇게 제조된 아미노산이나 저분자 펩타이드들에서 당뇨 개선, 인지기능 개선등의 효능이 발견되었고, 저분자 펩타이드 물질 중에서 어떤 것들이 이러한 효능을 나타내는지에 대한 추가적인 연구들이 이루어지고 있다. 그러나 10,000 이상의 큰 분자량의 고분자 실크 펩타이드에 대해서는, 이들 물질이 인체에서 흡수가 되지 않는다는 이유 때문에 이에 대한 제조나 연구가 전혀 이루어지고 있지 않은 실정이다. Conventional silk peptide production methods have been focused on developing a method of hydrolyzing a silk silk in the form of fiber using hydrochloric acid or an enzyme to decompose to a very low molecular weight peptide or amino acid level. Therefore, the molecular weight of the final product is mostly about 100 to 2,000 amino acids or about the size of the small molecule peptide, and the molecular weight of the large hydrolyzed products is composed of about 10,000. Since silk fiber cannot be digested and absorbed by itself, research has focused on how to lower the molecular weight by using various methods to increase digestive absorption rate, and the most representative method developed by using acid and enzyme It is a method of hydrolysis. Amino acids and low molecular weight peptides made by acids and enzymes could be absorbed by the human body more than 90%. The amino acids and low molecular weight peptides were found to be effective in improving diabetes and cognitive function. Further studies are underway to show this efficacy. However, for the high molecular weight high molecular silk peptide of 10,000 or more, there is no manufacturing or research on this because of the fact that these substances are not absorbed in the human body.
저분자 실크 펩타이드의 경우 본 발명에서와 같이 당뇨를 개선하는 효능을 가지고 있지만 그 작용기작은 전혀 다를 것으로 추정되고 있다. 저분자 실크 펩타이드의 경우, 그 구성 성분이 직접 인체에서 흡수되어 어떠한 메카니즘을 통하여 혈당을 낮출 것으로 추정되고 있는 반면, 고분자 실크 펩타이드는 거의 인체에 흡수 될 수 없기 때문에 전혀 다른 작용 기작을 통하여 혈당을 낮출 것으로 생각된다. 이렇듯 저분자 실크 펩타이드와 고분자 실크 펩타이드는 작용하는 물질도 전혀 다를 뿐만 아니라 작용 기작도 전혀 다를 것으로 판단된다.
The low molecular weight silk peptide has the effect of improving diabetes as in the present invention, but its mechanism of action is estimated to be completely different. In the case of low molecular weight silk peptides, it is estimated that its components are directly absorbed by the human body to lower blood sugar through any mechanism, while the high molecular weight silk peptides can lower blood sugar through completely different mechanisms because they can hardly be absorbed by the human body. I think. As such, the low-molecular silk peptides and the high-molecular silk peptides are not only different in substance but also in different mechanisms of action.
본 발명자들은 당뇨를 개선할 수 있는 실크 펩타이드 조성물을 개발하고자 예의 연구 노력한 결과, 가수 분해를 통하여 수득한 10,000 이상의 중량 평균 분자량을 갖는 고분자 실크 펩타이드 조성물이 우수한 당뇨 개선 기능을 갖는다는 것을 확인함으로써 본 발명을 완성하게 되었다.The present inventors earnestly researched to develop a silk peptide composition capable of improving diabetes, and as a result, the present invention was confirmed that the polymer silk peptide composition having a weight average molecular weight of 10,000 or more obtained through hydrolysis has excellent diabetes improvement function. To complete.
따라서, 본 발명의 목적은 당뇨 개선 기능을 갖는 실크 펩타이드 조성물을 제공하는 데 있다.
Accordingly, it is an object of the present invention to provide a silk peptide composition having a diabetic improvement function.
본 발명의 양태에 따르면, 본 발명은 실크 단백질을 가수 분해하여 중량 평균 분자량이 10,000-100,000이고 당뇨 개선 활성을 가지는 고분자 실크 펩타이드 조성물을 제공한다.According to an aspect of the present invention, the present invention provides a polymer silk peptide composition having a weight average molecular weight of 10,000-100,000 by hydrolyzing silk protein and having diabetes improvement activity.
본 발명의 방법에서 출발물질로 누에고치가 이용된다. 본 명세서에서 용어 "실크"는 견사 곤충이 토사하여 만든 섬유를 의미하며, 바람직하게는 누에 (Bombyx mori)가 토사하는 가잠사를 의미한다.A cocoon is used as starting material in the process of the invention. As used herein, the term "silk" means a fiber made by silkworm insects, and preferably means a silkworm sanded by a silkworm (Bombyx mori).
누에고치를 이루는 실크 단백질은 피브로인 및 세리신으로 이루어져 있고, 피브로인과 세리신은 각각 평균 75%와 25%의 비율로 존재한다. 피브로인 단백질과 세리신은 전혀 다른 아미노산 조성을 보이는 서로 다른 단백질이다. 최근의 연구 결과에 의하면 실크 피브로인은 H-사슬 (350 kDa) 및 L-사슬 (26 kDa)이 S-S 결합을 하고, 당단백질인 P25 (30 kDa)가 상기 두 사슬과 비공유 결합으로 연결된 구조를 하고 있으며, 각각 6:6:1의 몰 구성을 하고 있는 거대 단백질로 규명되었으며, 이러한 구조로 인해 결정영역과 비결정영역이 연속 교환 배열된 블록 형태의 고분자 성질을 가지게 된다.Silk cocoon silk protein consists of fibroin and sericin, fibroin and sericin are present on average 75% and 25%, respectively. Fibroin protein and sericin are different proteins with completely different amino acid compositions. According to recent research results, silk fibroin has a structure in which H-chain (350 kDa) and L-chain (26 kDa) are SS-bonded, and glycoprotein P25 (30 kDa) is non-covalently linked to the two chains. It was identified as a macromolecular protein having a mole composition of 6: 6: 1, and this structure has a polymer property of a block form in which crystalline and amorphous regions are continuously exchanged.
본 발명의 바람직한 구현예에 따르면, 이용되는 실크 단백질은 실크 피브로인이다.According to a preferred embodiment of the invention, the silk protein used is silk fibroin.
본 발명의 바람직한 구현예에 따르면, 실크 피브로인의 가수 분해는 (a) 정련, (b) 무기염 용액에서의 분해, (c) 무기염의 제거의 방법을 통해 실시될 수 있다. 상기한 방법에 의해 분해되어 생성된 실크 펩타이드의 중량 평균 분자량은 약 10,000-100,000의 범위를 나타낼 수 있으며, 당뇨 개선 기능성을 가진다.According to a preferred embodiment of the present invention, the hydrolysis of silk fibroin can be carried out through the method of (a) refining, (b) decomposition in inorganic salt solution, (c) removal of inorganic salt. The weight average molecular weight of the silk peptides produced by decomposition by the above-described method may be in the range of about 10,000-100,000, and has diabetes improving function.
상기 정련은 누에고치를 열수에서 가열하여 실시되는데, 바람직하게는 80~130℃, 보다 바람직하게는 120℃에서 가열하여 세리신을 제거한다. 또한 열수에 탄산나트륨이나 계면활성제를 첨가하여 실시할 수도 있다.The refining is carried out by heating the cocoon in hot water, preferably 80 to 130 ℃, more preferably at 120 ℃ to remove sericin. Moreover, it can also carry out by adding sodium carbonate and surfactant to hot water.
상기 무기염 용액에서의 분해는 통상적으로 염산염을 이용하는 데, 바람직하게는 염화칼슘, 염화마그네슘, 염화아연, 보다 바람직하게는 염화칼슘을 사용한다. 또한 여기에 에탄올을 추가로 혼합하여 사용할 수 있다. The decomposition in the inorganic salt solution is usually used hydrochloride, preferably calcium chloride, magnesium chloride, zinc chloride, more preferably calcium chloride. In addition, ethanol may be further mixed and used therein.
상기 단계 (b)는 실크 피브로인을 염화칼슘, 물 및 에탄올이 혼합된 용액에서 60-95℃에서 반응시켜 용해하여 실시하는 것이 바람직하며, 보다 바람직하게는 70-95℃, 가장 바람직하게는 75-85℃에서 용해한다. 이와 같은 칼슘염 용액에서의 분해에 의해 실크 피브로인은 분자량 10,000-50,000 정도의 비교적 고분자 펩타이드로 분해된다. Step (b) is preferably performed by dissolving silk fibroin in a solution containing calcium chloride, water and ethanol at 60-95 ° C, more preferably 70-95 ° C, most preferably 75-85 Dissolve at ° C. By the decomposition in the calcium salt solution, silk fibroin is decomposed into a relatively high molecular peptide of about 10,000-50,000 molecular weight.
상기 단계 (c)에서 염을 제거하는 방법은 당업계에 공지된 다양한 방법을 통하여 실시할 수 있으며, 예컨대, 투석, 한외여과, 겔 여과 크로마토그래피 또는 전기 탈염 방법 등이 있으며, 특정한 중량 분자량 범위만을 선택적으로 분리하기 위하여 이 방법들을 조합하여 사용할 수 있다. The method of removing the salt in step (c) may be carried out through various methods known in the art, for example, dialysis, ultrafiltration, gel filtration chromatography or electrodesalting, etc., and only a specific weight molecular weight range. These methods can be used in combination for selective separation.
본 발명의 방법에 의해 제조된 실크 펩타이드는 높은 분자량을 갖기 때문에 체내에서 흡수가 잘 되지 않는다. 실크 피브로인의 독특한 다공성 구조는 높은 흡착 성질을 가지기 때문에 실크 피브로인과 함께 섭취된 지방 성분을 강하게 흡착할 수 있다. 그 결과 실크 피브로인에 흡착된 지방 성분은 체내에 흡수되지 못하고 배설되어 지방의 흡수를 저해하게 되며, 그 결과 혈당 감소의 개선 효과를 가져올 수 있다.
Silk peptides prepared by the method of the present invention have a high molecular weight and are not well absorbed by the body. Silk fibroin's unique porous structure has high adsorption properties, so it can strongly adsorb fat components ingested with silk fibroin. As a result, the fat component adsorbed on the silk fibroin is not excreted in the body and is excreted to inhibit the absorption of fat, and as a result, it can bring about an effect of reducing blood sugar.
본 발명은 당뇨 개선 활성을 가지는 고분자 실크 펩타이드 조성물을 제공한다. 본 발명은 실크 단백질로부터 당뇨 개선의 활성을 가지며, 거의 체내에 흡수되지 않는 높은 분자량의 실크 펩타이드 조성물을 제공한다.
The present invention provides a polymer silk peptide composition having diabetes improving activity. The present invention provides a high molecular weight silk peptide composition having activity of diabetic improvement from silk protein and hardly absorbed into the body.
하기의 실시예에서 예증된 바와 같이, 본 발명의 방법에 의해 제조된 실크 펩타이드는 당뇨의 치료 및 예방에 이용될 수 있다.
As illustrated in the examples below, silk peptides prepared by the methods of the present invention can be used for the treatment and prevention of diabetes.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention more specifically, and the scope of the present invention is not limited by these examples according to the gist of the present invention.
실시예 1. 실크 피브로인의 정련Example 1 Refining Silk Fibroin
본 발명에 사용한 실크 단백질은 가잠 (Bombyx mori) 를 사육하여 얻은 누에고치에서 번데기를 제거하고 정련하여 사용하였다. 번데기를 제거한 누에고치에 50배의 물을 넣고 섭씨120도에서 20분간 가열하고, 깨끗한 물로 수세하고 건조시켜, 세리신 단백질이 제거된 순수한 실크 피브로인 단백질을 얻었다. The silk protein used in the present invention was used after removing pupa from the cocoon obtained by breeding the gambo (Bombyx mori). 50 times of water was added to the cocoon from which the pupa was removed, heated at 120 degrees Celsius for 20 minutes, washed with clean water and dried to obtain pure silk fibroin protein from which sericin protein was removed.
실시예 2. 고분자 실크 펩타이드의 제조방법Example 2. Preparation of Polymer Silk Peptides
실시예 1 에서 얻은 정련된 실크 피브로인 단백질을 5M 염화칼슘 용액에 넣고, 섭씨 90도로 가열하면서 에탄올을 가하여 실크 피브로인 단백질을 완전히 녹여 가수분해하였다. 거즈등을 여러겹 겹쳐서 번데기 조각등 커다란 이물질을 제거하고, 여과지 (Whatman No.1) 를 사용하여 불용성 물질을 제거하였다. 염화칼슘의 제거는 a) 물에 투석하는 방법, b) 전기탈염기를 사용하는 방법, c) 한외여과를 이용하는 방법, d) 겔크로마토그래피를 이용하는 방법을 이용하였다. 모든 방법에서 염화칼슘은 잘 제거되었으며, 이 후 작업에서 동일한 결과를 얻을 수 있었다. 다만, 전기탈염기 방법은 빠른 시간에 대량의 시료를 처리할 수 있는 장점이 있는 반면, 실크 단백질의 손실이 많은 단점이 있었다. 나머지 방법들은 대량의 시료를 처리하기 어려운 단점과 시간이 많이 걸리는 단점이 있는 반면, 실크 단백질의 손실이 적은 장점을 가지고 있었다. 염화칼슘이 제거된 고분자 실크 피브로인 펩타이드 용액을 동결 건조하여 분말로 제조하였다.
The refined silk fibroin protein obtained in Example 1 was placed in a 5M calcium chloride solution, and ethanol was added while heating at 90 degrees Celsius to completely dissolve and hydrolyze the silk fibroin protein. Multiple layers of gauze were stacked to remove large foreign objects such as pupa pieces, and filter paper (Whatman No. 1) was used to remove insoluble matters. Calcium chloride was removed by using a) dialysis in water, b) using an electrodesulfate, c) using ultrafiltration, and d) using gel chromatography. Calcium chloride was well removed in all methods and the same result was obtained in subsequent work. However, the electrodesalter method has the advantage of being able to process a large amount of samples in a fast time, while there are many disadvantages of silk protein loss. The remaining methods had the disadvantages of being difficult and time-consuming to process a large amount of samples, while having the advantage of low loss of silk protein. The calcium chloride-free polymeric silk fibroin peptide solution was freeze-dried to prepare a powder.
실시예 3. 고분자 실크 펩타이드의 분자량 측정Example 3. Determination of Molecular Weight of Polymer Silk Peptides
상기 실시예 2에서 제조된 고분자 실크 펩타이드에 대하여 겔 투과 크로마토그래피법에 의하여 분자량을 계산하였다. 0.2M sodium phosphate 완충용액에 고분자 실크 펩타이드를 녹이고, 크로마토그래피를 수행하여 280nm 흡광도 값으로부터 분자량의 분포를 계산하였으며, 실험 결과, 고분자 실크 펩타이드의 중량 평균 분자량은 26 kDa 이었다.
The molecular weight of the polymer silk peptide prepared in Example 2 was calculated by gel permeation chromatography. The polymer silk peptide was dissolved in 0.2 M sodium phosphate buffer and chromatographed to calculate the molecular weight distribution from the absorbance value of 280 nm. As a result, the weight average molecular weight of the polymer silk peptide was 26 kDa.
실시예 4. 고분자 실크 펩타이드의 혈당 개선 효과Example 4 Glucose Improvement Effects of Polymer Silk Peptides
임상실험 연구자는 혈당 수치는 정상치보다 높지만 아직 당뇨 치료를 받고 있지 않은 남녀 18명 (남자 6명, 여자 12명, 평균 연령 55.2±8.3 세) 을 대조군 6명, 실험군 12명으로 나누어 임상실험을 실시하였다. 고분자 실크 펩타이드 500mg 을 1일 3회, 식사하기 직전에 섭취하였으며 2개월동안 진행하였다. 임상실험을 시작하기 전에 각 항목에 대한 혈액 검사를 수행하였으며, 임상실험 시작 이 후에는 1개월 단위로 혈액 검사를 수행하였다. Investigators conducted clinical trials by dividing 18 men and women (6 males, 12 females, average age 55.2 ± 8.3 years old) into 6 control groups and 12 experimental groups. It was. 500 mg of polymer silk peptide was taken 3 times a day, just before meals, and proceeded for 2 months. Before starting the clinical trials, blood tests were performed on each item, and after the start of the clinical trials, blood tests were performed on a monthly basis.
검사 항목은 공복 혈당 측정이외에 당화 헤모글로빈을 추가로 측정하였다. 공복 혈당 측정은 측정하는 시점에 혈액에 존재하는 혈당을 측정하는 것이기 때문에 혈당이 제대로 조절되지 못하고 들쑥날쑥하게 변화하는 경우, 큰 오차를 가져오게 된다. 이러한 점을 보완할 수 있는 실험이 당화 헤모글로빈을 측정하는 것이다. 혈액에 존재하는 혈당은 적혈구에 있는 혈색소에 결합되는데, 이것은 적혈구의 수명이 다할 때까지 결합되어 있게 된다. 그러므로 당화 헤모글로빈 수치를 측정하게 되면 일정 기간동안의 평균적인 혈당 수준이 어느정도인지 가늠할 수 있게 된다. 실험 결과는 표 1 과 같다.
In addition to fasting blood glucose test items, glycated hemoglobin was measured. Fasting blood glucose measurement is a measure of the blood sugar present in the blood at the time of measurement, if the blood sugar is not properly controlled and jagged changes, it brings a big error. An experiment that can compensate for this is to measure glycated hemoglobin. Blood glucose in the blood binds to the hemoglobin in the red blood cells, which are bound to the end of the life of the red blood cells. Therefore, the measurement of glycated hemoglobin levels can be used to determine the average level of blood sugar over a period of time. The experimental results are shown in Table 1.
실험 결과 대조군에서는 혈당 및 당화헤모글로빈의 변화가 없었던 반면, 실험군에서는, 실험을 시작하기 전 당뇨환자 수준 (140 mg/dL 이상) 의 혈당 수치가 2개월 후에 거의 정상 수준 (80~110 mg/dL) 가까이 개선되었음을 확인할 수 있었다. 당화 헤모글로빈 수치도 실험을 시작하기 전 정상범위 (4.0~5.5%)를 크게 벗어난 수치가 정상범위를 향하여 지속적으로 감소하고 있음을 확인할 수 있다. 한번 헤모글로빈에 부착된 혈당은 적혈구가 수명을 다할 때까지 떨어지지 않는데, 적혈구의 수명이 120일에 달하기 때문에 수치가 급격하게 변화할 수 없고, 천천히 변화할 수 밖에 없다. 적혈구의 수명이 4개월에 달하는데도 2개월동안 상당히 수치가 내려간 것은 임상실험 시작 이후 새로 생성된 적혈구에 부착된 혈당이 상당히 적어서 전체적으로 평균 수치를 낮추어 주었기 때문이며, 이 결과 고분자 실크 펩타이드가 혈당을 낮추어 주는 효과가 탁월함을 확인할 수 있었다.
In the control group, there was no change in blood sugar and glycated hemoglobin, whereas in the experimental group, the blood glucose level of the diabetic patients (140 mg / dL or more) before starting the experiment was almost normal (80-110 mg / dL) after 2 months. It was confirmed that the improvement closer. Glycosylated hemoglobin levels also significantly decreased beyond the normal range (4.0-5.5%) before starting the experiment. Once the blood sugar attached to hemoglobin does not fall until the red blood cells have reached the end of their lifespan, the lifespan of the red blood cells reaches 120 days, so the numbers can not change rapidly, and can only change slowly. Although the lifespan of erythrocytes reached 4 months, the levels dropped significantly for 2 months because the blood sugar attached to newly created erythrocytes was significantly lower since the start of the clinical trial, which lowered the overall average. It was confirmed that the effect is excellent.
이상 살펴본 바와 같이, 본 발명에 의하여 제조된 고분자의 실크 펩타이드를 섭취함으로써, 당뇨 개선 기능을 가져 당뇨의 치료 및 예방을 위하여 사용될 수 있다. As described above, by taking the silk peptide of the polymer prepared according to the present invention, it has a diabetic improvement function can be used for the treatment and prevention of diabetes.
Claims (10)
Functional food composition for diabetic improvement produced by decomposition of silk protein, comprising a silk peptide having a weight average molecular weight of 10,000 to 100,000 as an active ingredient
The functional food composition for diabetic improvement of claim 1, wherein the silk protein is silk sericin or silk fibroin.
The functional food composition for diabetic improvement of claim 2, wherein the silk protein is silk fibroin.
The method of claim 1, wherein the decomposition of the silk protein is characterized in that it is carried out by a decomposition method selected from the group consisting of decomposition in calcium salt solution, acid hydrolysis, decomposition by a mixture solution of calcium salt and ethanol, and combinations thereof. Functional food composition for improving diabetes
The functional food composition for diabetic improvement of claim 1, wherein the weight average molecular weight of the silk peptide is 20,000-50,000.
The functional food composition for diabetic improvement of claim 5, wherein the weight average molecular weight of the silk peptide is more preferably 25,000 to 30,000.
The method of claim 4, wherein the degradation of the silk protein comprises: (a) dissolving silk fibroin in a solution containing calcium salt; (b) silk peptide composition having a diabetic improvement effect comprising removing calcium salt contained in the silk fibroin solution
The method of claim 4, wherein the calcium salt is a silk peptide composition having a diabetic improvement effect, characterized in that calcium chloride
The silk peptide composition of claim 7, wherein the calcium salt is removed from the method consisting of dialysis, ultrafiltration, gel chromatography, electrodesalting, and a combination thereof.
The method of claim 9 is the removal of calcium salt silk peptide composition having a diabetic improvement effect, characterized in that more preferably consisting of ultrafiltration method
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110118198A KR20130052878A (en) | 2011-11-14 | 2011-11-14 | Silk peptide effective for diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110118198A KR20130052878A (en) | 2011-11-14 | 2011-11-14 | Silk peptide effective for diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130052878A true KR20130052878A (en) | 2013-05-23 |
Family
ID=48662229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110118198A Ceased KR20130052878A (en) | 2011-11-14 | 2011-11-14 | Silk peptide effective for diabetes |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20130052878A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048805A1 (en) | 2013-09-30 | 2015-04-02 | Silk Therapeutics, Inc. | Silk potein fragment compositions and articles manufactured therefrom |
| CN109627309A (en) * | 2018-12-28 | 2019-04-16 | 浙江工业大学 | A method of silk peptide is prepared using serrapeptase hydrolysis fibroin |
-
2011
- 2011-11-14 KR KR1020110118198A patent/KR20130052878A/en not_active Ceased
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11298310B2 (en) | 2013-09-30 | 2022-04-12 | Evolved By Nature, Inc. | Stable silk protein fragment compositions |
| US11857664B2 (en) | 2013-09-30 | 2024-01-02 | Evolved By Nature, Inc. | Stable silk protein fragment compositions |
| JP7776545B2 (en) | 2013-09-30 | 2025-11-26 | エボルブド バイ ネイチャー， インコーポレイテッド | Silk protein fragment compositions and articles made therefrom |
| JP2021001198A (en) * | 2013-09-30 | 2021-01-07 | エボルブド バイ ネイチャー， インコーポレイテッド | Silk protein fragment compositions and articles manufactured therefrom |
| US10987294B2 (en) | 2013-09-30 | 2021-04-27 | Evolved By Nature, Inc. | Stable silk fibroin based pharmaceutical formulations |
| US11298311B2 (en) | 2013-09-30 | 2022-04-12 | Evolved By Nature, Inc. | Stable silk protein fragment compositions |
| EP3052203A4 (en) * | 2013-09-30 | 2017-08-23 | Silk Therapeutics Inc. | Silk protein fragment compositions and articles manufactured therefrom |
| JP7263298B2 (en) | 2013-09-30 | 2023-04-24 | エボルブド バイ ネイチャー， インコーポレイテッド | Silk protein fragment compositions and articles made therefrom |
| WO2015048805A1 (en) | 2013-09-30 | 2015-04-02 | Silk Therapeutics, Inc. | Silk potein fragment compositions and articles manufactured therefrom |
| US11857663B2 (en) | 2013-09-30 | 2024-01-02 | Evolved By Nature, Inc. | Stable silk protein fragment compositions |
| JP2022116179A (en) * | 2013-09-30 | 2022-08-09 | エボルブド バイ ネイチャー， インコーポレイテッド | Silk protein fragment compositions and articles made therefrom |
| JP7423688B2 (en) | 2013-09-30 | 2024-01-29 | エボルブド バイ ネイチャー， インコーポレイテッド | Silk protein fragment compositions and articles made therefrom |
| JP2024050635A (en) * | 2013-09-30 | 2024-04-10 | エボルブド バイ ネイチャー， インコーポレイテッド | Silk protein fragment compositions and articles made therefrom |
| EP4509520A3 (en) * | 2013-09-30 | 2025-10-22 | Evolved by Nature, Inc. | Silk protein fragment compositions and articles manufactured therefrom |
| CN109627309A (en) * | 2018-12-28 | 2019-04-16 | 浙江工业大学 | A method of silk peptide is prepared using serrapeptase hydrolysis fibroin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rajabimashhadi et al. | Collagen derived from fish industry waste: progresses and challenges | |
| Khan et al. | Importance of gelatin, nanoparticles and their interactions in the formulation of biodegradable composite films: A review | |
| Aramwit et al. | Formulation and characterization of silk sericin–PVA scaffold crosslinked with genipin | |
| KR102539012B1 (en) | Fibroin-derived protein composition | |
| Perez G et al. | Wound healing properties of Hylocereus undatus on diabetic rats | |
| de Souza et al. | Fish collagen for skin wound healing: A systematic review in experimental animal studies | |
| KR101071338B1 (en) | Method of Producing Collagen Peptide from Marine Organism and Collagen Peptide Produced by the Method | |
| CN107868808A (en) | A kind of method for improving bird's nest saliva free acid | |
| JP2011520927A (en) | Collagen peptide with immunity-enhancing activity derived from the yellow jellyfish and its preparation and use | |
| KR101916759B1 (en) | The Method of High-yield and High-purity Manufacturing of Allo-collagen Composition Extracted From Human origin | |
| KR20130053494A (en) | Preparation method of silk peptide improving diabet, hypercholesterolemia, and hyperlipidemia | |
| KR20200030779A (en) | Chelate collagen peptide and method for preparing the same | |
| KR20130052878A (en) | Silk peptide effective for diabetes | |
| JP2006111667A (en) | Sericin hydrogel and method for producing sericin porous body | |
| CN108977488B (en) | Elastin for intensive skin repair and preparation method thereof | |
| Kumari et al. | In vivo soft tissue regenerative potential of flax seed mucilage self-assembled collagen aerogels | |
| KR102240111B1 (en) | Cosmetic composition for moisturizing skin and improving skin wrinkles containing nano collagen peptide chelate mineral | |
| CN113754759A (en) | Process for extracting multiple nutritional ingredients from fish scales | |
| KR20130052910A (en) | Silk peptide for improving hypercholesterolemia and hyperlipidemia | |
| CN101307093B (en) | Method for separating and purifying collagen for biopharmaceutical use from sharkskin | |
| Wu et al. | Advances in research and application of fish scale collagen | |
| KR20060125995A (en) | How to make collagen from starfish | |
| Sanapala et al. | Sericin as food additive | |
| EP3864959B1 (en) | Material for pearl culturing, nucleus-inserting method, and composition of material for pearl culturing | |
| KR101534290B1 (en) | Silk sericin film with good mechanical properties and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20111114 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130416 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20131128 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130416 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |